Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Susceptibility to a parkinsonian toxin varies during primate development.

Experimental neurology·2012

Same author

Reduced locomotor responses to cocaine in ghrelin-deficient mice.

Neuroscience·2011

Same author

Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.

Neuroscience·2011

Same author

Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6.

Gene therapy·2009

Same author

Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF.

The Journal of comparative neurology·2009

Same author

Existing technologies to reduce specific toxicant emissions in cigarette smoke.

Tobacco control·2008

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

Aged monkeys as a partial model for Parkinson's disease.

P J Hurley¹, J D Elsworth, M C Whittaker

¹Department of Psychiatry, Yale University School of Medicine, 300 George Street 9th Floor, New Haven, CT 06510, USA.

Pharmacology, Biochemistry, and Behavior

|May 31, 2011

Summary

Aging in monkeys naturally induces parkinsonism, mirroring neurotoxin-induced Parkinson's disease (PD) symptoms and dopamine depletion. Aged monkeys exhibit motor and behavioral changes similar to PD, but do not respond to dopamine replacement therapies.

More Related Videos

The 6-hydroxydopamine Rat Model of Parkinson's Disease

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

Related Experiment Videos

Last Updated: Jun 1, 2026

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

The 6-hydroxydopamine Rat Model of Parkinson's Disease

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

Area of Science:

Neuroscience
Primatology
Gerontology

Background:

Parkinson's Disease (PD) shares biochemical pathways with natural aging, particularly involving dopaminergic system decline.
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is used to model PD by depleting dopamine in the nigrostriatal system.

Purpose of the Study:

To compare motor and behavioral changes in aged monkeys with MPTP-induced parkinsonism.
To investigate the extent to which natural aging mimics Parkinson's Disease.

Main Methods:

Aged monkeys were assessed using the Parkinson's factor score (Parkscore) and compared to young adults and MPTP-exposed monkeys.
Post-mortem striatal dopamine (DA) concentrations were measured and correlated with behavioral scores.
The efficacy of L-Dopa and DA-agonists was evaluated in aged monkeys.

Main Results:

Aged monkeys exhibited higher Parkscore ratings, indicating significant motor and behavioral deficits (tremor, eating problems, delayed initiation, poverty of movement).
Post-mortem analysis revealed a 63% reduction in ventral putamen DA in aged monkeys compared to young adults, with greater depletion in the putamen than the caudate nucleus.
Dopamine replacement therapies did not effectively reverse the parkinsonian measures in aged monkeys.

Conclusions:

Naturally aged monkeys display a parkinsonism profile similar to MPTP-induced PD, characterized by selective dopamine depletion in the putamen.
This aging-related dopamine depletion pattern in monkeys mirrors that observed in human Parkinson's Disease.
Aged monkeys, like aging humans, show limited therapeutic benefit from standard dopamine replacement treatments.